Strides Delivers Strong Performance with FY26 EBITDA at ₹9,253m, Operational PAT at ₹5,181m, 50% YoY Growth

Ex-US Markets Outperform with 21% YoY Revenue Growth; Disciplined Execution Expands EBITDA Margin to 19%

Strides Board Recommends a Dividend of ₹5 per share

FY2026 Performance Highlights

• US Market Revenue at ₹24,897m ($284m), Grew 2% YoY
• Ex-US Market Revenue at ₹22,404m ($254m), reported a strong growth of 21% YoY
• Reported Net Debt at ₹14,365m, impacted by Fx (₹) depreciation of ₹1,115m
• Net Debt to EBITDA improved to 1.55x in FY26 from 1.9x in FY25
• RoCE increased to 15.8% in FY26 from 14.9% in FY25
• Operational PAT at ₹5,181m, Grew 50.3% YoY
• Operational EPS at ₹56.2

National : Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q4FY26) and Full Year (FY26) ended March 31, 2026.

Financial Highlights (In ₹m)

Particulars	Q4FY26	Q4FY25	YoY	Q3FY26	QoQ	FY26	FY25	YoY
Revenue	13,235	11,904	11.20%	11,946	10.80%	48,587	45,653	6.40%
Gross Margin	7,872	6,914	13.90%	7,317	7.60%	29,000	25,854	12.20%
Gross Margin %	59.50%	58.10%	140bps	61.20%	-170bps	59.70%	56.60%	310bps
EBITDA	2,397	2,179	10.00%	2,359	1.60%	9,253	8,208	15.30%
EBITDA %	18.10%	18.30%	-20bps	19.80%	-170bps	19.00%	17.60%	140bps
Operational PAT	1,357	1,130	20.00%	1,282	5.90%	5,181	3,447	50.30%
Operational EPS (₹)	14.7	12.3	20.00%	13.9	5.80%	56.2	37.5	50.10%
Reported PAT	1,293	856	51.00%	2,081	-37.90%	5,745	4,094	40.30%
Reported EPS (₹)	13.8	8.9	54.30%	21.9	-37.20%	60.3	44	37.00%

Reported PAT = PAT from continuing operations; Operational PAT = Reported PAT excluding exceptional items and one time income

Badree Komandur, MD s Group CEO, commented on the performance and said, “Strides continued to deliver strong performance across profitability, efficiency, and growth metrics during FY26. This was primarily driven by the Ex-US markets, which recorded a growth of 21% YoY. Our continued focus on profitability drove gross margin expansion of 310bps YoY and EBITDA margin improvement of 140bps YoY to 19%. Operational PAT and EPS grew by 50% YoY, reflecting strong operating leverage. Our calibrated strategy in Ex-US markets is delivering results, with these markets outpacing overall company growth. The US business remained stable during the year, though impacted by a weaker flu season in the second half. Despite ongoing geopolitical uncertainties and a challenging external environment, we are committed to delivering to long term sustainable and profitable growth.”